Flag of the European Union EU Clinical Trials Register Help

Clinical trials for PD-1

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    424 result(s) found for: PD-1. Displaying page 4 of 22.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2021-002823-40 Sponsor Protocol Number: NOUS-209-01 Start Date*: 2021-12-21
    Sponsor Name:Nouscom S.r.l.
    Full Title: A Phase I/IIa, Multicenter, Open-Label Study of Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors
    Medical condition: Locally advanced unresectable or metastatic, microsatellite instability high (MSI-H) or dMMR CRC who are eligible for anti-PD-1 1st line of treatment
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing) IT (Trial now transitioned) BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-000864-42 Sponsor Protocol Number: IFX-1-P2.8 Start Date*: 2021-04-27
    Sponsor Name:InflaRx GmbH
    Full Title: OPEN LABEL, MULTICENTER PHASE II STUDY OF THE C5A-ANTIBODY IFX-1 ALONE OR IFX-1 + PEMBROLIZUMAB IN PATIENTS WITH PD-1- OR PD-L1-RESISTANT/REFRACTORY LOCALLY ADVANCED OR METASTATIC CUTANEOUS SQUAMOU...
    Medical condition: Locally advanced or metastatic cutaneous squamous cell carcinoma (cSCC)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041823 Squamous cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Prematurely Ended) BE (Completed)
    Trial results: View results
    EudraCT Number: 2021-004471-13 Sponsor Protocol Number: PM1183-C-008-21 Start Date*: 2022-08-03
    Sponsor Name:Pharma Mar, S.A.
    Full Title: A Randomized, Multicenter, Open-label, Phase III Study of Lurbinectedin Single-Agent or Lurbinectedin in Combination with Irinotecan versus Investigator’s Choice (Topotecan or Irinotecan) in Relaps...
    Medical condition: Small Cell Lung Cancer (SCLC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041067 Small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) BE (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) BG (Trial now transitioned) HU (Trial now transitioned) IT (Trial now transitioned) AT (Trial now transitioned) DK (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-003718-16 Sponsor Protocol Number: CA209-066 Start Date*: 2013-04-04
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 3, Randomized, Double-Blind Study of BMS-936558 vs Dacarbazine in Subjects with Previously Untreated Unresectable or Metastatic Melanoma Country specific Protocol Amendment 05, dated 09-...
    Medical condition: Melanoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10053571 Melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FI (Completed) SE (Completed) ES (Completed) DK (Completed) NO (Completed) IT (Completed) PL (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2017-001041-27 Sponsor Protocol Number: R2810-ONC-16111 Start Date*: 2018-10-15
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (Anti-PD-1 Antibody), Platinum based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy...
    Medical condition: Non-Small Cell Lung Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing) LT (Completed) GB (GB - no longer in EU/EEA) AT (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-003375-19 Sponsor Protocol Number: B8011006 Start Date*: 2020-07-20
    Sponsor Name:Pfizer Inc.
    Full Title: A Phase 3, Multinational, Randomized, Open-Label, Three Parallel-Arm Study of PF-06801591, an anti-PD-1 antibody, in Combination with Bacillus Calmette-Guerin (BCG Induction With or Without BCG Mai...
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10022877 Invasive bladder cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) GB (GB - no longer in EU/EEA) PT (Completed) BE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-001409-34 Sponsor Protocol Number: MO39171 Start Date*: 2017-11-20
    Sponsor Name:F. Hoffman-La Roche Ltd.
    Full Title: A PHASE III/IV, SINGLE ARM, MULTICENTER STUDY OF ATEZOLIZUMAB (TECENTRIQ) TO INVESTIGATE LONG-TERM SAFETY AND EFFICACY IN PREVIOUSLY-TREATED PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL C...
    Medical condition: Malignant neoplasm of bronchus and lung (nsc) adv.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SI (Completed) SE (Completed) DK (Completed) LV (Completed) PL (Completed) GB (GB - no longer in EU/EEA) NL (Completed) ES (Ongoing) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-002521-30 Sponsor Protocol Number: HBI-8000-303 Start Date*: 2022-03-07
    Sponsor Name:HUYABIO International, LLC
    Full Title: A Multicenter, Randomized, Double-Blind Phase 3 Study of HBI-8000 Combined with Nivolumab versus Placebo with Nivolumab in Patients with Unresectable or Metastatic Melanoma Not Previously Treated w...
    Medical condition: Metastatic or unresectable melanoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027481 Metastatic melanoma LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Trial now transitioned) FR (Trial now transitioned) DE (Trial now transitioned) AT (Prematurely Ended) ES (Ongoing) BE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-002226-27 Sponsor Protocol Number: HLX10-020-SCLC302 Start Date*: 2022-11-17
    Sponsor Name:Shanghai Henlius Biotech, Inc.
    Full Title: A Randomized, Double-Blind, International Multicenter, Phase III Study to Evaluate the Anti-Tumor Efficacy and Safety of HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) or Pla...
    Medical condition: Patients with Limited-Stage Small Cell Lung Cancer (LS-SCLC) at stage I-III of the AJCC 8th edition of the cancer staging
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041067 Small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) DE (Trial now transitioned) HU (Trial now transitioned) PL (Trial now transitioned) AT (Trial now transitioned) LV (Trial now transitioned) CZ (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-002267-33 Sponsor Protocol Number: OCTO-089 Start Date*: 2017-06-13
    Sponsor Name:University of Oxford
    Full Title: A parallel group phase I/II marker lesion study to assess the safety, tolerability and efficacy of intravenous or intravesical pembrolizumab in intermediate risk recurrent non-muscle invasive bladd...
    Medical condition: Intermediate risk recurrent non-muscle invasive bladder cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005056 Bladder neoplasm PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-000232-34 Sponsor Protocol Number: NASIR-HCC Start Date*: 2017-09-11
    Sponsor Name:Clínica Universidad de Navarra/Universidad de Navarra
    Full Title: A multicenter, open-label, single-arm study of the safety and antitumoral efficacy of nivolumab in combination with selective internal radiation therapy (SIRT) using SIR-Spheres for the treatment o...
    Medical condition: Hepatocellular carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073071 Hepatocellular carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2012-001840-23 Sponsor Protocol Number: CA209-038 Start Date*: 2019-07-12
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: An exploratory study of the biologic effects of Nivolumab and Ipilimumab Monotherapy and Nivolumab in Combination with Ipilimumab Treatment in Subjects with Advanced melanoma (Unresectable or metas...
    Medical condition: Advanced or Metastatic Melanoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025671 Malignant melanoma stage IV PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025670 Malignant melanoma stage III PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10053571 Melanoma LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-004065-25 Sponsor Protocol Number: CCR4251 Start Date*: 2015-07-28
    Sponsor Name:Royal Marsden
    Full Title: Randomised Phase II Trial of Pembrolizumab and Radiotherapy in Melanoma
    Medical condition: Advanced or unresectable melanoma.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2022-003063-21 Sponsor Protocol Number: ENX-CL-04-002a Start Date*: 2023-02-14
    Sponsor Name:Enlivex Therapeutics RDO, Ltd.
    Full Title: A Phase 1/2a Study Evaluating Allocetra-OTS as Monotherapy or in Combination with Anti-PD-1 Therapy for the Treatment of Advanced Solid Tumor Malignancy
    Medical condition: Advanced Solid Tumor Malignancy
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065147 Malignant solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-005741-31 Sponsor Protocol Number: AIO-YMO/TRK-0415 Start Date*: 2016-12-02
    Sponsor Name:AIO-Studien-gGmbH
    Full Title: Fostering efficacy of anti – PD-1 – treatment: Nivolumab plus radiotherapy in advanced NSCLC
    Medical condition: metastatic non-squamous Non-Small Cell Lung Cancer (Lung adenocarcinoma metastatic and Large cell lung cancer metastatic)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10069730 Large cell lung cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10064049 Lung adenocarcinoma metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-002643-28 Sponsor Protocol Number: CA209-8JD Start Date*: 2019-02-25
    Sponsor Name:Amsterdam UMC, location VUmc
    Full Title: Safety and tolerability of neoadjuvant nivolumab for locally advanced resectable oral cancer, combined with [18F]BMS-986192 / [18F]-FDG PET imaging and immunomonitoring for response prediction.
    Medical condition: Stage III/IV resectable oral squamous cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10030961 Oral cancer stage unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2018-004490-27 Sponsor Protocol Number: 18POUM06 Start Date*: 2019-09-11
    Sponsor Name:INSTITUT CLAUDIUS REGAUD
    Full Title: A multicentric Phase II, open-label study evaluating the efficacy of the combination of hypofractionated stereotactic radiation therapy with the anti-PDL1 immune checkpoint inhibitor Durvalumab in ...
    Medical condition: Non-small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-004110-25 Sponsor Protocol Number: TUD-PEMAZA-068 Start Date*: 2018-12-14
    Sponsor Name:Technische Universität Dresden
    Full Title: MRD-guided treatment with pembrolizumab and azacitidine in NPM1mut AML patients with an imminent hematological relapse
    Medical condition: Patients with NPM1mut AML >= 18 years in CR presenting with MRD after conventional chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-005142-29 Sponsor Protocol Number: UC-0107/1718 Start Date*: 2018-08-30
    Sponsor Name:UNICANCER
    Full Title: PD-(L)1 iNhibitors with concurrent IRadiation at VAried tumour sites in advanced Non-small cell lung cAncer
    Medical condition: Advanced (stage IIIB/IIIC/IV) NSCLC patients eligible for treatment with a PD-1 or PD-L1 antagonist according to the European Marketing Authorisation in a first line or a second line
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-003555-16 Sponsor Protocol Number: 21469 Start Date*: 2020-12-11
    Sponsor Name:BAYER AG
    Full Title: An Open-Label Study of Regorafenib in Combination with Pembrolizumab in Patients with Advanced or Metastatic Hepatocellular Carcinoma (HCC) after PD-1/PD-L1 Immune Checkpoint Inhibitors
    Medical condition: A type of liver cancer which may have spread to nearby tissue and is unlikely to be cured or controlled with treatment
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10019828 Hepatocellular carcinoma non-resectable LLT
    Population Age: Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 18 11:18:01 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA